A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Peter Mollee, John Reynolds, Wojt Janowski, Hang Quach, Philip Campbell, Simon Gibbs, Sophie Lee, James D'Rozario, Kerry Taylor, Tara Cochrane, Craig Wallington-Beddoe, Fiona Kwok, Nicholas Weber, Ian Kerridge, Helen Weston, P. Joy Ho, Noemi Horvath, Flora Yuen, Andrew Spencer

Research output: Contribution to journalMeeting Abstractpeer-review

Abstract

IntroductionDaratumumab, when added to standard of care regimens in relapsed and untreated myeloma, has consistently demonstrated significant improvements in response rates, induction of MRD negative responses and progression-free survival (PFS) while proving highly tolerable with minor increases in overall regimen toxicity. In non-transplant eligible patients daratumumab has been added in randomized studies to lenalidomide and dexamethasone (Rd) and bortezomib, melphalan and prednisolone (VMP) backbones, but not to the VCD regimen. Furthermore, the randomized studies excluded a significant proportion of patients with comorbidities so the benefit of daratumumab in a frail, elderly myeloma population remains untested.
Original languageEnglish
Number of pages4
JournalBlood
Volume136
Issue numberSupplement 1
DOIs
Publication statusPublished - 5 Nov 2020
Event62nd ASH Annual Meeting and Exposition -
Duration: 5 Dec 20208 Dec 2020
Conference number: 62

Keywords

  • Bortezomib
  • Cyclophosphamide
  • Dexamethasone
  • VCD
  • Daratumumab
  • VCDD
  • Myeloma
  • untreated myeloma

Fingerprint

Dive into the research topics of 'A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)'. Together they form a unique fingerprint.

Cite this